Navigation Links
Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases

dvance CC-11050 and other compounds from this class of oral TNF alpha inhibitors, as potential novel oral therapies for chronic inflammatory diseases.

"CC-10004 is a unique oral therapy that demonstrates reasonable efficacy and favorable safety profile in a moderate to severe psoriasis setting. The drug is clearly working," said Kim Papp, M.D., Ph.D., Assistant Clinical Professor of Medicine at the University of Western Ontario, Canada and a principle investigator of the Phase II study.

Adverse side effects in patients receiving CC-10004 were mild and well tolerated. Overall, the percentage of patients who reported at least one adverse event in the CC-10004 twice daily arm (54%) was equivalent to that experienced with the placebo arm of the study (60%).

"These positive results validate the potential of our oral class of anti- inflammatory compounds," said Sol J. Barer, Ph.D., Chairman and Chief Executive Officer of Celgene Corporation. "We plan to evaluate multiple opportunities across a broad range of debilitating inflammatory diseases where there are limited effective oral treatment options for these devastating conditions."

About the Phase II Study

This Phase II study was a multicenter, randomized, double blind, placebo- controlled, parallel-group, dose comparison efficacy study in 260 patients with moderate-to-severe plaque-type psoriasis who were candidates for systemic therapy. Patients who participated in this study were required to have a minimum of a 6-month history of moderate-to-severe plaque-type psoriasis prior to enrollment.

About Chronic Inflammatory Diseases

Chronic inflammatory diseases are caused by persistent stimulus to tissues in the body over a prolonged period of time resulting in inflammation. This class of diseases includes immune-mediated conditions, such as rheumatoid arthritis and psoriasis, where a person's immune system attacks their own body tissues trying to heal and repair them, but ul
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:6/1/2015)... 2015 The nuclear imaging market is estimated ... CAGR of 12.08%. Nuclear medicine is the use of ... types of Nuclear imaging used commonly are PET and ... for nuclear medicine applications like nuclear cardiology procedures. However, ... global shortage of molybdenum-99 isotope which is in turn ...
(Date:6/1/2015)... PARK, Calif. , June 1, 2015 ... device company that is providing innovative evidence-based solutions for ... has commenced an underwritten public offering of its common ... Nevro and 2,459,175 shares to be sold by certain ... the underwriters a 30-day option to purchase up to ...
(Date:6/1/2015)... 1, 2015 NEOVIA ONCOLOGY Ltd. ... the development and commercialization of novel, multi-function drugs ... met with the U.S. Food and Drug Administration ... an Investigational New Drug (IND) application for its ... of the meeting, Neovia has clarified details of ...
Breaking Medicine Technology:North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 2North America Nuclear Imaging Market - Growth, Trends And Forecasts (2014 - 2019) 3Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Neovia Oncology Announces First IND Meeting 2
... and WILMINGTON, Del., Dec. 21 Eli Lilly and ... (Nasdaq: INCY ) announced today that they have ... for the development and commercialization of Incyte,s oral JAK1/JAK2 ... and autoimmune diseases. The lead compound, INCB28050, is currently ...
... , CARLSBAD, Calif., Dec. 21 Isis ... will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. ... license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). ... and OncoGenex that has completed a successful Phase 2 program ...
Cached Medicine Technology:Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 2Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 3Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 4Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 5Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 6Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Kathy Everette-Gaines as a 2015-2016 inductee into its ... recognized with this prestigious distinction for leadership in ... exclusively for professional women, boasting more than 700,000 ... “I’m pleased to welcome Kathy into this exceptional ...
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Lenita F. Cornett, DSL, LSSBB (C), First Sergeant ... its VIP Woman of the Year Circle. She is ... military. NAPW is the nation's leading networking organization exclusively ... over 200 operating Local Chapters. , “I'm pleased to ...
(Date:6/1/2015)... June 01, 2015 Carson Energy also ... their investors IRA transactions. AdvantaIRA Trust, LLC is the ... the ability to fund positions using IRA’s does 2 ... on a project, even if there current cash position ... additional funding source for Carson and their investors to ...
(Date:6/1/2015)... York, New York (PRWEB) June 01, 2015 ... ( http://www.testosteronelawsuithub.com/ ) has amended the Case Management ... Inc.’s AndroGel testosterone gel. The Amended Order which ... of Illinois on May 29, 2015, directs the parties ... Court by August 10, 2015 that outlines parameters and ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Atagi Plastic ... have been named an Ultherapy® Ultra Treatment ... Surgery and Skin Aesthetics is one of only six ... a premier treatment provider. , Atagi Plastic Surgery ... the Denver area has led the practice to earn ...
Breaking Medicine News(10 mins):Health News:The National Association of Professional Women Inducts Kathy Everette-Gaines, Community Relations Coordinator, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lenita F. Cornett, First Sergeant of the US Military, Into its VIP Professional Woman of the Year Circle 2Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 4Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2
... reduce the risk of asthma, according to Danish researchers. ... at the European Respiratory Society,s Annual Congress in Amsterdam, found ... the risk of developing the condition. The research ... yrs of age. All participants completed a questionnaire at the ...
... , SATURDAY, Sept. 24 (HealthDay News) -- Poor children ... to infection and disease -- than kids from higher-income ... the study findings revealed, some disadvantaged children grow up ... mother. Upward mobility also has been cited as ...
... Emerging Regions) Center at the University of Oklahoma is ... to focus on the life-sustaining resource, clean water. The ... to unsafe water, inadequate sanitation and poor hygiene than ... scarcity, but rather poverty, inequality and government failures. ...
... HealthDay Reporter , FRIDAY, Sept. 23 (HealthDay News) -- ... be vaccinated against human papillomavirus, a sexually transmitted disease that ... does not extend to boys and young men. At ... whether males also should be vaccinated for human papillomavirus, or ...
... disabilities increased in the U.S. among non-elderly adults during ... Mojtabai, MD, PhD, of the Johns Hopkins Bloomberg School ... found the prevalence of disability attributed to other chronic ... remained unchanged. The findings will appear in the November ...
... , THURSDAY, Sept. 22 (HealthDay News) -- Bed bug infestations ... than 100 Americans have become sickened from exposure to the ... across seven states, researchers said, and bed bug insecticide exposure ... of cases involved misuse," said report co-author Dr. Geoffrey Calvert, ...
Cached Medicine News:Health News:Good Moms Seem to Help Poor Kids Become Healthy Adults 2Health News:CDC Considers Vaccinating Boys, Not Just Girls, for HPV 2Health News:CDC Considers Vaccinating Boys, Not Just Girls, for HPV 3Health News:Bed Bug Insecticides Causing Sickness, Officials Warn 2Health News:Bed Bug Insecticides Causing Sickness, Officials Warn 3Health News:Bed Bug Insecticides Causing Sickness, Officials Warn 4
... the leading developer of laser diagnostics for ... Heidelberg Retina Tomograph 3 (HRT3), a newly-enhanced ... assessment, diagnosis and management of glaucoma. ,Like ... to produce a topographical image of a ...
The Escape Basket offers a side-by-side approach, unique to the market, for using a nitinol basket and holmium laser fiber together-providing physician control and independent manipulation of both th...
Simple, Effective Laparoscopic Irrigation Pumps from the Market Leader...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
Medicine Products: